Skip to main content

Table 1 Treatment of subcutaneous heterotopic human pancreatic BxPC-3 tumors in nude mice

From: Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer

Treatment groups Completion of treatment Tumor volume (mm3) Tumor weight (g) Body weight (g)
Mean Range Mean Range Mean Range
Control 5/8a 816 524–999 596 373–790 26 24–28
IFN-β 7/8a 660 281–1370 507 161–852 26 24–28
Gemcitabine 5/7a + b 745 402–1187 628 166–1121 25 24–27
IFN-β + gemcitabine 6/8 447c 213–572 492 161–958 26 24–28
  1. a Number of mice that completed 4 weeks of treatment. Mice were sacrificed before the end of treatment if the wellbeing of the animal could not be maintained (in all these mice this was due to ulceration of the tumor)
  2. b One mice died before the start of the treatment
  3. c P < 0.05 versus control